Research programme: CDX bi-specific antibodies - Hemogenyx

Drug Profile

Research programme: CDX bi-specific antibodies - Hemogenyx

Latest Information Update: 08 Jan 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Hemogenyx
  • Class Bispecific antibodies; Cell therapies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Stem cell engraftment

Most Recent Events

  • 30 Oct 2017 Hemogenyx has patent pending for CDX Bi-specific antibodies in USA (Hemogenyx website, October 2017)
  • 30 Oct 2017 Preclinical trials in Stem cell engraftment in United Kingdom (IV)
  • 30 Oct 2017 Hemogenyx files an IND application with the FDA for Stemcell engraftment before October 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top